Alan Oglesby

2.9k total citations · 1 hit paper
55 papers, 2.2k citations indexed

About

Alan Oglesby is a scholar working on Infectious Diseases, Endocrinology, Diabetes and Metabolism and Virology. According to data from OpenAlex, Alan Oglesby has authored 55 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Infectious Diseases, 13 papers in Endocrinology, Diabetes and Metabolism and 12 papers in Virology. Recurrent topics in Alan Oglesby's work include HIV/AIDS drug development and treatment (19 papers), HIV/AIDS Research and Interventions (19 papers) and HIV Research and Treatment (12 papers). Alan Oglesby is often cited by papers focused on HIV/AIDS drug development and treatment (19 papers), HIV/AIDS Research and Interventions (19 papers) and HIV Research and Treatment (12 papers). Alan Oglesby collaborates with scholars based in United States, United Kingdom and Canada. Alan Oglesby's co-authors include Adam Gordois, Paul Scuffham, Arran Shearer, Janet Tobian, Kristina Secnik, Risa P. Hayes, Andrew Palmer, William J. Valentine, Aaron I. Vinik and Etta J. Vinik and has published in prestigious journals such as Diabetes Care, Journal of Bone and Mineral Research and Bone.

In The Last Decade

Alan Oglesby

53 papers receiving 2.1k citations

Hit Papers

The Health Care Costs of Diabetic Peripheral Neuropathy i... 2003 2026 2010 2018 2003 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The Health Care Costs of Diabetic Peripheral Neuropathy in the U.S.
    2003 572 citations Adam Gordois, Paul Scuffham et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alan Oglesby United States 25 820 372 371 306 292 55 2.2k
Ernesto Maddaloni Italy 26 953 1.2× 310 0.8× 616 1.7× 158 0.5× 130 0.4× 95 2.1k
Luba Nalysnyk United States 14 270 0.3× 453 1.2× 994 2.7× 436 1.4× 73 0.3× 28 3.2k
Helen Keen Australia 33 208 0.3× 204 0.5× 996 2.7× 121 0.4× 56 0.2× 157 4.1k
Andrew Wilson Australia 28 487 0.6× 652 1.8× 702 1.9× 475 1.6× 108 0.4× 77 3.0k
Lorenzo Scappaticcio Italy 26 1.4k 1.8× 173 0.5× 465 1.3× 134 0.4× 140 0.5× 94 2.1k
Pasquale Ambrosino Italy 31 222 0.3× 206 0.6× 495 1.3× 175 0.6× 306 1.0× 131 2.8k
Shawn Malone Canada 31 566 0.7× 547 1.5× 446 1.2× 1.3k 4.2× 60 0.2× 168 4.5k
Yu Cho Woo Hong Kong 25 944 1.2× 213 0.6× 530 1.4× 166 0.5× 175 0.6× 112 2.3k
Nitin Kapoor India 22 441 0.5× 322 0.9× 336 0.9× 241 0.8× 103 0.4× 250 1.9k
Betty Wong Canada 24 182 0.2× 169 0.5× 292 0.8× 417 1.4× 35 0.1× 56 2.6k

Countries citing papers authored by Alan Oglesby

Since Specialization
Citations

This map shows the geographic impact of Alan Oglesby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Oglesby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Oglesby more than expected).

Fields of papers citing papers by Alan Oglesby

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Oglesby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Oglesby. The network helps show where Alan Oglesby may publish in the future.

Co-authorship network of co-authors of Alan Oglesby

This figure shows the co-authorship network connecting the top 25 collaborators of Alan Oglesby. A scholar is included among the top collaborators of Alan Oglesby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan Oglesby. Alan Oglesby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brogan, Anita J., et al.. (2024). Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States. PharmacoEconomics. 42(4). 447–461. 1 indexed citations
2.
Kumar, Princy, Amanda Clarke, Miguel García Deltoro, et al.. (2024). Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA Study. AIDS and Behavior. 29(1). 235–245.
3.
4.
5.
Mills, Anthony, Kathy L. Schulman, Jennifer S Fusco, et al.. (2021). Virologic Outcomes Among People Living With Human Immunodeficiency Virus With High Pretherapy Viral Load Burden Initiating on Common Core Agents. Open Forum Infectious Diseases. 8(8). ofab363–ofab363. 3 indexed citations
6.
Priest, Julie, Rachel H. Bhak, Maral DerSarkissian, et al.. (2021). Retrospective analysis of adherence to HIV treatment and healthcare utilization in a commercially insured population. Journal of Medical Economics. 24(1). 1204–1211. 6 indexed citations
7.
Oglesby, Alan, et al.. (2021). 853. Real-World Persistency of Patients Receiving Tenofovir-Based Pre-Exposure Prophylaxis for the Prevention of HIV Infection in the US. Open Forum Infectious Diseases. 8(Supplement_1). S516–S517. 1 indexed citations
8.
Priest, Julie, et al.. (2019). Clinical characteristics and treatment patterns among US patients with HIV.. PubMed. 25(12). 580–586. 4 indexed citations
9.
Priest, Julie, et al.. (2019). Benchmarking HIV Quality Measures Across US Payer Types. Population Health Management. 23(2). 146–156. 5 indexed citations
10.
11.
Ward, Douglas, Moti Ramgopal, David J. Riedel, et al.. (2019). 2485. Real-world Experience with Dolutegravir Plus Rilpivirine Two-Drug Regimen. Open Forum Infectious Diseases. 6(Supplement_2). S861–S861. 1 indexed citations
12.
Ke, Xuehua, et al.. (2015). A Retrospective Administrative Claims Database Evaluation of the Utilization of Belimumab in US Managed Care Settings. Clinical Therapeutics. 37(12). 2852–2863. 12 indexed citations
13.
Pockett, Rhys, Daniel Castellano, Phil McEwan, et al.. (2009). The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. European Journal of Cancer Care. 19(6). 755–760. 97 indexed citations
14.
Matza, Louis S., Matthew D. Rousculp, Karen G. Malley, Kristina S. Boye, & Alan Oglesby. (2008). The longitudinal link between visual acuity and health-related quality of life in patients with diabetic retinopathy. Health and Quality of Life Outcomes. 6(1). 95–95. 45 indexed citations
15.
Boye, Kristina S., Louis S. Matza, Alan Oglesby, et al.. (2006). Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health and Quality of Life Outcomes. 4(1). 80–80. 63 indexed citations
16.
Oglesby, Alan, Kristina Secnik, John Barron, Ibrahim Al‐Zakwani, & Maureen J. Lage. (2006). The association between diabetes related medical costs and glycemic control: A retrospective analysis. Cost Effectiveness and Resource Allocation. 4(1). 1–1. 110 indexed citations
17.
Gordois, Adam, Paul Scuffham, Arran Shearer, & Alan Oglesby. (2004). The health care costs of diabetic nephropathy in the United States and the United Kingdom. Journal of Diabetes and its Complications. 18(1). 18–26. 81 indexed citations
18.
Palmer, Andrew, Stéphane Roze, William J. Valentine, et al.. (2004). What Impact Would Pancreatic Beta-cell Preservation Have on Life Expectancy, Quality-adjusted Life Expectancy and Costs of Complications in Patients with Type 2 Diabetes? A Projection Using the CORE Diabetes Model. Current Medical Research and Opinion. 20(sup1). S59–S66. 13 indexed citations
19.
Gordois, Adam, Paul Scuffham, Arran Shearer, & Alan Oglesby. (2003). The healthcare costs of diabetic peripheral neuropathy in the UK. (Cost-of-illness study). RADIOISOTOPES. 6(2). 62–73. 16 indexed citations
20.
Kanis, J. A., Olof Johnell, Anders Odén, et al.. (2002). Intervention thresholds for osteoporosis. Bone. 31(1). 26–31. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ernesto Maddaloni Breakdown of academic impact, for papers by Luba Nalysnyk Breakdown of academic impact, for papers by Helen Keen Breakdown of academic impact, for papers by Andrew Wilson Breakdown of academic impact, for papers by Lorenzo Scappaticcio Breakdown of academic impact, for papers by Pasquale Ambrosino Breakdown of academic impact, for papers by Shawn Malone Breakdown of academic impact, for papers by Yu Cho Woo Breakdown of academic impact, for papers by Nitin Kapoor Breakdown of academic impact, for papers by Betty Wong
Rankless by CCL
2026